Literature DB >> 11991698

A reduction in serum cytokine levels parallels healing of venous ulcers in patients undergoing compression therapy.

M A Murphy1, W P Joyce, C Condron, D Bouchier-Hayes.   

Abstract

INTRODUCTION: vascular endothelial growth factor (VEGF) and tumour necrosis factor alpha (TNF(alpha)) have been specifically implicated in the tissue damage associated with chronic venous disease (CVD). Furthermore, production of both factors is known to be upregulated in vessel wall cells subject to hypertension. The aim of this study was to determine the local venous levels of VEGF and TNF(alpha) in limbs with venous ulcers before and after treatment with graduated compression. PATIENTS AND METHODS: eight patients with venous ulcers and 8 patients with varicose veins only were included in the study. For ulcer patients, serum samples were taken from the superficial veins in lower limbs and repeated after 4 weeks of treatment with 4-layered graduated compression. Serum from the arms of the same patients served as controls. Determination of the concentrations of VEGF and TNF(alpha) proteins were performed with sandwich enzyme-linked immunosorbent assays.
RESULTS: both groups of patients had elevated levels of VEGF and TNF(alpha). In patients with venous ulcers there was a reduction in the levels of both cytokines to below control values with treatment. These changes correlated with healing of the ulcers as determined by reduction in ulcer size.
CONCLUSION: these data, for the first time, suggest a central role for both TNF(alpha) and VEGF in the pathogenesis of venous ulceration which may constitute a causative link between venous hypertension and tissue pathology. Copyright 2002 Harcourt Publishers Limited.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11991698     DOI: 10.1053/ejvs.2002.1597

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  7 in total

Review 1.  Medical Treatment for Postthrombotic Syndrome.

Authors:  Federico Silva Palacios; Suman Wasan Rathbun
Journal:  Semin Intervent Radiol       Date:  2017-03       Impact factor: 1.513

2.  Use of platelet-rich plasma to facilitate wound healing.

Authors:  Yuliya Menchisheva; Ulmeken Mirzakulova; Rudolf Yui
Journal:  Int Wound J       Date:  2018-11-15       Impact factor: 3.315

3.  New aspect of anti-inflammatory action of lipo-prostaglandinE1 in the management of collagen diseases-related skin ulcer.

Authors:  Hiroyuki Murota; Yorihisa Kotobuki; Noriko Umegaki; Mamori Tani; Ichiro Katayama
Journal:  Rheumatol Int       Date:  2008-05-07       Impact factor: 2.631

4.  Deletion of a tumor necrosis superfamily gene in mice leads to impaired healing that mimics chronic wounds in humans.

Authors:  Melissa L Petreaca; Danh Do; Sandeep Dhall; Darcie McLelland; Avo Serafino; Julia Lyubovitsky; Neal Schiller; Manuela M Martins-Green
Journal:  Wound Repair Regen       Date:  2012 May-Jun       Impact factor: 3.617

5.  Case Report: Rehabilitation for Lower Extremity Pain Due to Venous Stasis in a Patient With Multisystem Inflammatory Syndrome in Children.

Authors:  Tokio Kinoshita; Yukihide Nishimura; Yasunori Umemoto; Yumi Koike; Ken Kouda; Takahiro Ogawa; Tomohiro Suenaga; Fumihiro Tajima
Journal:  Front Pediatr       Date:  2022-01-06       Impact factor: 3.418

Review 6.  Cytokines and Venous Leg Ulcer Healing-A Systematic Review.

Authors:  Ewa A Burian; Lubna Sabah; Tonny Karlsmark; Klaus Kirketerp-Møller; Christine J Moffatt; Jacob P Thyssen; Magnus S Ågren
Journal:  Int J Mol Sci       Date:  2022-06-10       Impact factor: 6.208

7.  Extracellular matrix remodelling in response to venous hypertension: proteomics of human varicose veins.

Authors:  Javier Barallobre-Barreiro; Rahmi Oklu; Marc Lynch; Marika Fava; Ferheen Baig; Xiaoke Yin; Temo Barwari; David N Potier; Hassan Albadawi; Marjan Jahangiri; Karen E Porter; Michael T Watkins; Sanjay Misra; Julianne Stoughton; Manuel Mayr
Journal:  Cardiovasc Res       Date:  2016-04-11       Impact factor: 10.787

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.